Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Inclusion Criteria:

• Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
• Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
• Is concomitantly on one or more prescription medications or illicit drugs.

Exclusion Criteria:

• Treated with DAAs other than G/P.
• History of decompensated cirrhosis.
• Had Hepatitis-B virus (HBV) infection.
• Had hepatocellular carcinoma (HCC).